nodes	percent_of_prediction	percent_of_DWPC	metapath
Paroxetine—CYP2B6—malignant glioma	0.379	0.54	CbGaD
Paroxetine—SLC6A3—malignant glioma	0.323	0.46	CbGaD
Paroxetine—HTR2A—choroid plexus—malignant glioma	0.00656	0.108	CbGeAlD
Paroxetine—SLC6A3—telencephalic ventricle—malignant glioma	0.00396	0.0653	CbGeAlD
Paroxetine—HTR2A—cerebellar cortex—malignant glioma	0.0033	0.0545	CbGeAlD
Paroxetine—HTR2A—pons—malignant glioma	0.00233	0.0385	CbGeAlD
Paroxetine—HTR2A—vertebral column—malignant glioma	0.00232	0.0382	CbGeAlD
Paroxetine—TACR1—brainstem—malignant glioma	0.00213	0.0351	CbGeAlD
Paroxetine—HTR2A—telencephalic ventricle—malignant glioma	0.00192	0.0317	CbGeAlD
Paroxetine—TACR1—telencephalon—malignant glioma	0.00189	0.0312	CbGeAlD
Paroxetine—HTR2A—pineal body—malignant glioma	0.00167	0.0275	CbGeAlD
Paroxetine—TACR1—spinal cord—malignant glioma	0.00132	0.0218	CbGeAlD
Paroxetine—Myasthenia—Carmustine—malignant glioma	0.00117	0.00809	CcSEcCtD
Paroxetine—Aphasia—Carmustine—malignant glioma	0.00114	0.00784	CcSEcCtD
Paroxetine—Tooth disorder—Temozolomide—malignant glioma	0.0011	0.00757	CcSEcCtD
Paroxetine—Aphasia—Temozolomide—malignant glioma	0.0011	0.00757	CcSEcCtD
Paroxetine—Parosmia—Temozolomide—malignant glioma	0.0011	0.00757	CcSEcCtD
Paroxetine—Hypokinesia—Carmustine—malignant glioma	0.00109	0.00753	CcSEcCtD
Paroxetine—Paranoia—Carmustine—malignant glioma	0.00108	0.00746	CcSEcCtD
Paroxetine—TACR1—central nervous system—malignant glioma	0.00107	0.0177	CbGeAlD
Paroxetine—SLC6A3—brainstem—malignant glioma	0.00107	0.0177	CbGeAlD
Paroxetine—Thrombosis—Carmustine—malignant glioma	0.00104	0.00718	CcSEcCtD
Paroxetine—HTR2A—endothelium—malignant glioma	0.00103	0.017	CbGeAlD
Paroxetine—Myopathy—Temozolomide—malignant glioma	0.00102	0.007	CcSEcCtD
Paroxetine—CHRM4—central nervous system—malignant glioma	0.00101	0.0167	CbGeAlD
Paroxetine—Stupor—Carmustine—malignant glioma	0.000987	0.00681	CcSEcCtD
Paroxetine—SLC6A4—brainstem—malignant glioma	0.000982	0.0162	CbGeAlD
Paroxetine—Scotoma—Carmustine—malignant glioma	0.000971	0.00669	CcSEcCtD
Paroxetine—Vaginal haemorrhage—Temozolomide—malignant glioma	0.000963	0.00664	CcSEcCtD
Paroxetine—Menorrhagia—Temozolomide—malignant glioma	0.000963	0.00664	CcSEcCtD
Paroxetine—CHRM2—telencephalon—malignant glioma	0.000954	0.0157	CbGeAlD
Paroxetine—SLC6A3—telencephalon—malignant glioma	0.000951	0.0157	CbGeAlD
Paroxetine—HTR2A—blood vessel—malignant glioma	0.000951	0.0157	CbGeAlD
Paroxetine—Herpes zoster—Temozolomide—malignant glioma	0.000946	0.00652	CcSEcCtD
Paroxetine—Extrapyramidal disorder—Temozolomide—malignant glioma	0.000946	0.00652	CcSEcCtD
Paroxetine—Scotoma—Temozolomide—malignant glioma	0.000938	0.00647	CcSEcCtD
Paroxetine—Abscess—Carmustine—malignant glioma	0.000932	0.00642	CcSEcCtD
Paroxetine—Otitis media—Temozolomide—malignant glioma	0.000915	0.00631	CcSEcCtD
Paroxetine—Hyperaesthesia—Temozolomide—malignant glioma	0.000908	0.00626	CcSEcCtD
Paroxetine—SLC6A4—telencephalon—malignant glioma	0.000872	0.0144	CbGeAlD
Paroxetine—CHRM1—telencephalon—malignant glioma	0.000868	0.0143	CbGeAlD
Paroxetine—SLC6A2—brainstem—malignant glioma	0.000865	0.0143	CbGeAlD
Paroxetine—Endocrine disorder—Temozolomide—malignant glioma	0.000859	0.00593	CcSEcCtD
Paroxetine—TACR1—brain—malignant glioma	0.000853	0.0141	CbGeAlD
Paroxetine—Disturbance in attention—Temozolomide—malignant glioma	0.000822	0.00567	CcSEcCtD
Paroxetine—Breast pain—Temozolomide—malignant glioma	0.000817	0.00563	CcSEcCtD
Paroxetine—Amenorrhoea—Temozolomide—malignant glioma	0.000811	0.00559	CcSEcCtD
Paroxetine—Thinking abnormal—Carmustine—malignant glioma	0.000805	0.00555	CcSEcCtD
Paroxetine—CHRM4—brain—malignant glioma	0.000802	0.0132	CbGeAlD
Paroxetine—CHRM5—central nervous system—malignant glioma	0.00079	0.013	CbGeAlD
Paroxetine—Leukocytosis—Carmustine—malignant glioma	0.000784	0.00541	CcSEcCtD
Paroxetine—Hyperbilirubinaemia—Temozolomide—malignant glioma	0.000783	0.0054	CcSEcCtD
Paroxetine—CHRM3—telencephalon—malignant glioma	0.000777	0.0128	CbGeAlD
Paroxetine—Herpes simplex—Temozolomide—malignant glioma	0.000773	0.00533	CcSEcCtD
Paroxetine—SLC6A2—telencephalon—malignant glioma	0.000767	0.0127	CbGeAlD
Paroxetine—Gait disturbance—Carmustine—malignant glioma	0.000755	0.00521	CcSEcCtD
Paroxetine—Coordination abnormal—Carmustine—malignant glioma	0.000751	0.00518	CcSEcCtD
Paroxetine—Neck pain—Carmustine—malignant glioma	0.000746	0.00514	CcSEcCtD
Paroxetine—Pulmonary embolism—Carmustine—malignant glioma	0.000737	0.00508	CcSEcCtD
Paroxetine—Gait disturbance—Temozolomide—malignant glioma	0.00073	0.00503	CcSEcCtD
Paroxetine—Coordination abnormal—Temozolomide—malignant glioma	0.000726	0.005	CcSEcCtD
Paroxetine—Vaginal inflammation—Temozolomide—malignant glioma	0.000712	0.00491	CcSEcCtD
Paroxetine—Pulmonary embolism—Temozolomide—malignant glioma	0.000712	0.00491	CcSEcCtD
Paroxetine—Phosphatase alkaline increased—Temozolomide—malignant glioma	0.000712	0.00491	CcSEcCtD
Paroxetine—Depressed level of consciousness—Carmustine—malignant glioma	0.000712	0.00491	CcSEcCtD
Paroxetine—Urinary incontinence—Carmustine—malignant glioma	0.000712	0.00491	CcSEcCtD
Paroxetine—Candida infection—Carmustine—malignant glioma	0.000704	0.00485	CcSEcCtD
Paroxetine—Neuropathy—Carmustine—malignant glioma	0.000692	0.00477	CcSEcCtD
Paroxetine—Depressed level of consciousness—Temozolomide—malignant glioma	0.000688	0.00474	CcSEcCtD
Paroxetine—Urinary incontinence—Temozolomide—malignant glioma	0.000688	0.00474	CcSEcCtD
Paroxetine—SLC6A3—midbrain—malignant glioma	0.000683	0.0113	CbGeAlD
Paroxetine—Candida infection—Temozolomide—malignant glioma	0.00068	0.00469	CcSEcCtD
Paroxetine—Coma—Carmustine—malignant glioma	0.000674	0.00464	CcSEcCtD
Paroxetine—Vaginal infection—Temozolomide—malignant glioma	0.000673	0.00464	CcSEcCtD
Paroxetine—Aplastic anaemia—Temozolomide—malignant glioma	0.000669	0.00461	CcSEcCtD
Paroxetine—Neuropathy—Temozolomide—malignant glioma	0.000669	0.00461	CcSEcCtD
Paroxetine—Neoplasm—Carmustine—malignant glioma	0.000667	0.0046	CcSEcCtD
Paroxetine—SLC6A3—spinal cord—malignant glioma	0.000666	0.011	CbGeAlD
Paroxetine—Neoplasm—Temozolomide—malignant glioma	0.000644	0.00444	CcSEcCtD
Paroxetine—Abnormal vision—Carmustine—malignant glioma	0.000643	0.00443	CcSEcCtD
Paroxetine—Sepsis—Carmustine—malignant glioma	0.00064	0.00441	CcSEcCtD
Paroxetine—Mental disability—Carmustine—malignant glioma	0.00064	0.00441	CcSEcCtD
Paroxetine—CHRM5—brain—malignant glioma	0.000627	0.0103	CbGeAlD
Paroxetine—SLC6A4—midbrain—malignant glioma	0.000626	0.0103	CbGeAlD
Paroxetine—ABCB1—blood vessel—malignant glioma	0.000623	0.0103	CbGeAlD
Paroxetine—Abnormal vision—Temozolomide—malignant glioma	0.000621	0.00428	CcSEcCtD
Paroxetine—Phlebitis—Carmustine—malignant glioma	0.000621	0.00428	CcSEcCtD
Paroxetine—Mental disability—Temozolomide—malignant glioma	0.000618	0.00426	CcSEcCtD
Paroxetine—Thrombophlebitis—Carmustine—malignant glioma	0.000618	0.00426	CcSEcCtD
Paroxetine—Diabetes mellitus—Carmustine—malignant glioma	0.000615	0.00424	CcSEcCtD
Paroxetine—SLC6A4—spinal cord—malignant glioma	0.000611	0.0101	CbGeAlD
Paroxetine—Ear pain—Temozolomide—malignant glioma	0.000606	0.00418	CcSEcCtD
Paroxetine—SLC6A2—medulla oblongata—malignant glioma	0.000603	0.00994	CbGeAlD
Paroxetine—Thrombophlebitis—Temozolomide—malignant glioma	0.000597	0.00412	CcSEcCtD
Paroxetine—Blood alkaline phosphatase increased—Temozolomide—malignant glioma	0.000595	0.0041	CcSEcCtD
Paroxetine—Eye pain—Carmustine—malignant glioma	0.000593	0.00409	CcSEcCtD
Paroxetine—Gastroenteritis—Temozolomide—malignant glioma	0.000583	0.00402	CcSEcCtD
Paroxetine—Injury—Carmustine—malignant glioma	0.000582	0.00401	CcSEcCtD
Paroxetine—Vascular purpura—Temozolomide—malignant glioma	0.000578	0.00399	CcSEcCtD
Paroxetine—Deafness—Temozolomide—malignant glioma	0.000578	0.00399	CcSEcCtD
Paroxetine—Hepatic failure—Temozolomide—malignant glioma	0.000575	0.00397	CcSEcCtD
Paroxetine—Eye pain—Temozolomide—malignant glioma	0.000573	0.00395	CcSEcCtD
Paroxetine—Amnesia—Carmustine—malignant glioma	0.00057	0.00393	CcSEcCtD
Paroxetine—HTR2A—embryo—malignant glioma	0.000567	0.00935	CbGeAlD
Paroxetine—Amnesia—Temozolomide—malignant glioma	0.00055	0.0038	CcSEcCtD
Paroxetine—Dermatitis exfoliative—Temozolomide—malignant glioma	0.000548	0.00378	CcSEcCtD
Paroxetine—Thirst—Temozolomide—malignant glioma	0.000543	0.00375	CcSEcCtD
Paroxetine—CHRM2—central nervous system—malignant glioma	0.000542	0.00894	CbGeAlD
Paroxetine—SLC6A3—central nervous system—malignant glioma	0.000541	0.00892	CbGeAlD
Paroxetine—Hyponatraemia—Carmustine—malignant glioma	0.000537	0.0037	CcSEcCtD
Paroxetine—Purpura—Temozolomide—malignant glioma	0.000537	0.0037	CcSEcCtD
Paroxetine—Diplopia—Carmustine—malignant glioma	0.000535	0.00369	CcSEcCtD
Paroxetine—Gastrointestinal haemorrhage—Carmustine—malignant glioma	0.000535	0.00369	CcSEcCtD
Paroxetine—SLC6A3—cerebellum—malignant glioma	0.000528	0.00871	CbGeAlD
Paroxetine—HTR2A—brainstem—malignant glioma	0.00052	0.00857	CbGeAlD
Paroxetine—Diplopia—Temozolomide—malignant glioma	0.000517	0.00357	CcSEcCtD
Paroxetine—Face oedema—Carmustine—malignant glioma	0.000517	0.00356	CcSEcCtD
Paroxetine—Affect lability—Temozolomide—malignant glioma	0.000509	0.00351	CcSEcCtD
Paroxetine—Ataxia—Carmustine—malignant glioma	0.000503	0.00347	CcSEcCtD
Paroxetine—HTR2A—retina—malignant glioma	0.000501	0.00827	CbGeAlD
Paroxetine—Face oedema—Temozolomide—malignant glioma	0.000499	0.00344	CcSEcCtD
Paroxetine—SLC6A4—central nervous system—malignant glioma	0.000495	0.00817	CbGeAlD
Paroxetine—Liver function test abnormal—Carmustine—malignant glioma	0.000494	0.00341	CcSEcCtD
Paroxetine—CHRM1—central nervous system—malignant glioma	0.000493	0.00814	CbGeAlD
Paroxetine—Mood swings—Temozolomide—malignant glioma	0.00049	0.00338	CcSEcCtD
Paroxetine—Hypokalaemia—Carmustine—malignant glioma	0.000487	0.00336	CcSEcCtD
Paroxetine—Ataxia—Temozolomide—malignant glioma	0.000486	0.00335	CcSEcCtD
Paroxetine—Dehydration—Temozolomide—malignant glioma	0.000481	0.00332	CcSEcCtD
Paroxetine—Dry skin—Temozolomide—malignant glioma	0.000474	0.00327	CcSEcCtD
Paroxetine—CYP2D6—brainstem—malignant glioma	0.000473	0.00781	CbGeAlD
Paroxetine—Muscular weakness—Carmustine—malignant glioma	0.000472	0.00325	CcSEcCtD
Paroxetine—Hypokalaemia—Temozolomide—malignant glioma	0.000471	0.00324	CcSEcCtD
Paroxetine—Breast disorder—Temozolomide—malignant glioma	0.000467	0.00322	CcSEcCtD
Paroxetine—Toxic epidermal necrolysis—Temozolomide—malignant glioma	0.000466	0.00321	CcSEcCtD
Paroxetine—Aspartate aminotransferase increased—Temozolomide—malignant glioma	0.000466	0.00321	CcSEcCtD
Paroxetine—Dysphagia—Carmustine—malignant glioma	0.000463	0.00319	CcSEcCtD
Paroxetine—HTR2A—telencephalon—malignant glioma	0.000461	0.00761	CbGeAlD
Paroxetine—Alanine aminotransferase increased—Temozolomide—malignant glioma	0.000456	0.00314	CcSEcCtD
Paroxetine—Muscular weakness—Temozolomide—malignant glioma	0.000456	0.00314	CcSEcCtD
Paroxetine—Dysphagia—Temozolomide—malignant glioma	0.000447	0.00308	CcSEcCtD
Paroxetine—CHRM3—central nervous system—malignant glioma	0.000442	0.00728	CbGeAlD
Paroxetine—Pancytopenia—Carmustine—malignant glioma	0.000439	0.00303	CcSEcCtD
Paroxetine—SLC6A2—central nervous system—malignant glioma	0.000436	0.00719	CbGeAlD
Paroxetine—Sweating increased—Temozolomide—malignant glioma	0.000435	0.003	CcSEcCtD
Paroxetine—CHRM2—brain—malignant glioma	0.00043	0.0071	CbGeAlD
Paroxetine—Bronchitis—Temozolomide—malignant glioma	0.00043	0.00296	CcSEcCtD
Paroxetine—SLC6A3—brain—malignant glioma	0.000429	0.00708	CbGeAlD
Paroxetine—Pancytopenia—Temozolomide—malignant glioma	0.000424	0.00293	CcSEcCtD
Paroxetine—CYP2D6—telencephalon—malignant glioma	0.00042	0.00693	CbGeAlD
Paroxetine—Dysuria—Temozolomide—malignant glioma	0.000418	0.00288	CcSEcCtD
Paroxetine—Hyperglycaemia—Carmustine—malignant glioma	0.000417	0.00288	CcSEcCtD
Paroxetine—Pneumonia—Carmustine—malignant glioma	0.000415	0.00286	CcSEcCtD
Paroxetine—Pollakiuria—Temozolomide—malignant glioma	0.000413	0.00285	CcSEcCtD
Paroxetine—Erectile dysfunction—Temozolomide—malignant glioma	0.000412	0.00284	CcSEcCtD
Paroxetine—Depression—Carmustine—malignant glioma	0.000411	0.00284	CcSEcCtD
Paroxetine—Photosensitivity reaction—Temozolomide—malignant glioma	0.000408	0.00281	CcSEcCtD
Paroxetine—Weight increased—Temozolomide—malignant glioma	0.000407	0.0028	CcSEcCtD
Paroxetine—Weight decreased—Temozolomide—malignant glioma	0.000404	0.00279	CcSEcCtD
Paroxetine—Neuropathy peripheral—Carmustine—malignant glioma	0.000404	0.00279	CcSEcCtD
Paroxetine—Hyperglycaemia—Temozolomide—malignant glioma	0.000403	0.00278	CcSEcCtD
Paroxetine—Stomatitis—Carmustine—malignant glioma	0.000402	0.00277	CcSEcCtD
Paroxetine—Urinary tract infection—Carmustine—malignant glioma	0.000401	0.00276	CcSEcCtD
Paroxetine—Pneumonia—Temozolomide—malignant glioma	0.000401	0.00276	CcSEcCtD
Paroxetine—Depression—Temozolomide—malignant glioma	0.000397	0.00274	CcSEcCtD
Paroxetine—Stevens-Johnson syndrome—Temozolomide—malignant glioma	0.000395	0.00272	CcSEcCtD
Paroxetine—SLC6A4—brain—malignant glioma	0.000393	0.00649	CbGeAlD
Paroxetine—CHRM1—brain—malignant glioma	0.000392	0.00646	CbGeAlD
Paroxetine—Neuropathy peripheral—Temozolomide—malignant glioma	0.000391	0.00269	CcSEcCtD
Paroxetine—Stomatitis—Temozolomide—malignant glioma	0.000388	0.00268	CcSEcCtD
Paroxetine—Urinary tract infection—Temozolomide—malignant glioma	0.000387	0.00267	CcSEcCtD
Paroxetine—Hepatobiliary disease—Temozolomide—malignant glioma	0.000377	0.0026	CcSEcCtD
Paroxetine—Sinusitis—Temozolomide—malignant glioma	0.000374	0.00258	CcSEcCtD
Paroxetine—Haemoglobin—Carmustine—malignant glioma	0.000372	0.00257	CcSEcCtD
Paroxetine—ABCB1—embryo—malignant glioma	0.000372	0.00613	CbGeAlD
Paroxetine—Haemorrhage—Carmustine—malignant glioma	0.00037	0.00255	CcSEcCtD
Paroxetine—Hypoaesthesia—Carmustine—malignant glioma	0.000368	0.00254	CcSEcCtD
Paroxetine—Hallucination—Carmustine—malignant glioma	0.000368	0.00254	CcSEcCtD
Paroxetine—Oedema peripheral—Carmustine—malignant glioma	0.000365	0.00251	CcSEcCtD
Paroxetine—Connective tissue disorder—Carmustine—malignant glioma	0.000364	0.00251	CcSEcCtD
Paroxetine—HTR2A—medulla oblongata—malignant glioma	0.000362	0.00598	CbGeAlD
Paroxetine—Haemoglobin—Temozolomide—malignant glioma	0.00036	0.00248	CcSEcCtD
Paroxetine—Haemorrhage—Temozolomide—malignant glioma	0.000358	0.00247	CcSEcCtD
Paroxetine—Hepatitis—Temozolomide—malignant glioma	0.000358	0.00247	CcSEcCtD
Paroxetine—Visual impairment—Carmustine—malignant glioma	0.000357	0.00246	CcSEcCtD
Paroxetine—Hallucination—Temozolomide—malignant glioma	0.000356	0.00245	CcSEcCtD
Paroxetine—Hypoaesthesia—Temozolomide—malignant glioma	0.000356	0.00245	CcSEcCtD
Paroxetine—Pharyngitis—Temozolomide—malignant glioma	0.000355	0.00245	CcSEcCtD
Paroxetine—Oedema peripheral—Temozolomide—malignant glioma	0.000352	0.00243	CcSEcCtD
Paroxetine—Connective tissue disorder—Temozolomide—malignant glioma	0.000352	0.00242	CcSEcCtD
Paroxetine—CHRM3—brain—malignant glioma	0.000351	0.00578	CbGeAlD
Paroxetine—SLC6A2—brain—malignant glioma	0.000346	0.00571	CbGeAlD
Paroxetine—Eye disorder—Carmustine—malignant glioma	0.000346	0.00239	CcSEcCtD
Paroxetine—Visual impairment—Temozolomide—malignant glioma	0.000345	0.00238	CcSEcCtD
Paroxetine—Flushing—Carmustine—malignant glioma	0.000344	0.00237	CcSEcCtD
Paroxetine—Erythema multiforme—Temozolomide—malignant glioma	0.000338	0.00233	CcSEcCtD
Paroxetine—Eye disorder—Temozolomide—malignant glioma	0.000334	0.00231	CcSEcCtD
Paroxetine—Tinnitus—Temozolomide—malignant glioma	0.000334	0.0023	CcSEcCtD
Paroxetine—Flushing—Temozolomide—malignant glioma	0.000332	0.00229	CcSEcCtD
Paroxetine—Cardiac disorder—Temozolomide—malignant glioma	0.000332	0.00229	CcSEcCtD
Paroxetine—HTR2A—midbrain—malignant glioma	0.000331	0.00546	CbGeAlD
Paroxetine—Arrhythmia—Carmustine—malignant glioma	0.000331	0.00228	CcSEcCtD
Paroxetine—ABCB1—retina—malignant glioma	0.000329	0.00542	CbGeAlD
Paroxetine—Alopecia—Carmustine—malignant glioma	0.000327	0.00226	CcSEcCtD
Paroxetine—Angiopathy—Temozolomide—malignant glioma	0.000325	0.00224	CcSEcCtD
Paroxetine—Mental disorder—Carmustine—malignant glioma	0.000324	0.00224	CcSEcCtD
Paroxetine—Immune system disorder—Temozolomide—malignant glioma	0.000323	0.00223	CcSEcCtD
Paroxetine—HTR2A—spinal cord—malignant glioma	0.000323	0.00533	CbGeAlD
Paroxetine—Mediastinal disorder—Temozolomide—malignant glioma	0.000322	0.00222	CcSEcCtD
Paroxetine—Erythema—Carmustine—malignant glioma	0.000322	0.00222	CcSEcCtD
Paroxetine—Malnutrition—Carmustine—malignant glioma	0.000322	0.00222	CcSEcCtD
Paroxetine—CYP2B6—central nervous system—malignant glioma	0.000321	0.0053	CbGeAlD
Paroxetine—Chills—Temozolomide—malignant glioma	0.000321	0.00221	CcSEcCtD
Paroxetine—Alopecia—Temozolomide—malignant glioma	0.000316	0.00218	CcSEcCtD
Paroxetine—Mental disorder—Temozolomide—malignant glioma	0.000313	0.00216	CcSEcCtD
Paroxetine—Back pain—Carmustine—malignant glioma	0.000312	0.00215	CcSEcCtD
Paroxetine—Malnutrition—Temozolomide—malignant glioma	0.000311	0.00215	CcSEcCtD
Paroxetine—Erythema—Temozolomide—malignant glioma	0.000311	0.00215	CcSEcCtD
Paroxetine—Dysgeusia—Temozolomide—malignant glioma	0.000305	0.0021	CcSEcCtD
Paroxetine—Vision blurred—Carmustine—malignant glioma	0.000304	0.00209	CcSEcCtD
Paroxetine—ABCB1—telencephalon—malignant glioma	0.000302	0.00498	CbGeAlD
Paroxetine—Tremor—Carmustine—malignant glioma	0.000302	0.00208	CcSEcCtD
Paroxetine—Back pain—Temozolomide—malignant glioma	0.000301	0.00208	CcSEcCtD
Paroxetine—Anaemia—Carmustine—malignant glioma	0.000298	0.00205	CcSEcCtD
Paroxetine—Agitation—Carmustine—malignant glioma	0.000296	0.00204	CcSEcCtD
Paroxetine—Vision blurred—Temozolomide—malignant glioma	0.000294	0.00202	CcSEcCtD
Paroxetine—Tremor—Temozolomide—malignant glioma	0.000292	0.00201	CcSEcCtD
Paroxetine—Ill-defined disorder—Temozolomide—malignant glioma	0.000289	0.00199	CcSEcCtD
Paroxetine—Leukopenia—Carmustine—malignant glioma	0.000288	0.00199	CcSEcCtD
Paroxetine—Anaemia—Temozolomide—malignant glioma	0.000288	0.00198	CcSEcCtD
Paroxetine—Agitation—Temozolomide—malignant glioma	0.000286	0.00197	CcSEcCtD
Paroxetine—Angioedema—Temozolomide—malignant glioma	0.000285	0.00196	CcSEcCtD
Paroxetine—CYP2C8—brain—malignant glioma	0.000284	0.00469	CbGeAlD
Paroxetine—Malaise—Temozolomide—malignant glioma	0.000281	0.00194	CcSEcCtD
Paroxetine—Vertigo—Temozolomide—malignant glioma	0.00028	0.00193	CcSEcCtD
Paroxetine—Convulsion—Carmustine—malignant glioma	0.000279	0.00193	CcSEcCtD
Paroxetine—Leukopenia—Temozolomide—malignant glioma	0.000279	0.00192	CcSEcCtD
Paroxetine—Hypertension—Carmustine—malignant glioma	0.000278	0.00192	CcSEcCtD
Paroxetine—Palpitations—Temozolomide—malignant glioma	0.000275	0.0019	CcSEcCtD
Paroxetine—Myalgia—Carmustine—malignant glioma	0.000274	0.00189	CcSEcCtD
Paroxetine—Chest pain—Carmustine—malignant glioma	0.000274	0.00189	CcSEcCtD
Paroxetine—Anxiety—Carmustine—malignant glioma	0.000273	0.00189	CcSEcCtD
Paroxetine—Cough—Temozolomide—malignant glioma	0.000272	0.00187	CcSEcCtD
Paroxetine—Convulsion—Temozolomide—malignant glioma	0.00027	0.00186	CcSEcCtD
Paroxetine—Hypertension—Temozolomide—malignant glioma	0.000269	0.00185	CcSEcCtD
Paroxetine—Confusional state—Carmustine—malignant glioma	0.000265	0.00183	CcSEcCtD
Paroxetine—Arthralgia—Temozolomide—malignant glioma	0.000265	0.00183	CcSEcCtD
Paroxetine—Myalgia—Temozolomide—malignant glioma	0.000265	0.00183	CcSEcCtD
Paroxetine—Anxiety—Temozolomide—malignant glioma	0.000264	0.00182	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.000263	0.00182	CcSEcCtD
Paroxetine—Oedema—Carmustine—malignant glioma	0.000263	0.00181	CcSEcCtD
Paroxetine—HTR2A—central nervous system—malignant glioma	0.000262	0.00432	CbGeAlD
Paroxetine—Discomfort—Temozolomide—malignant glioma	0.000262	0.00181	CcSEcCtD
Paroxetine—Infection—Carmustine—malignant glioma	0.000261	0.0018	CcSEcCtD
Paroxetine—Dry mouth—Temozolomide—malignant glioma	0.000259	0.00179	CcSEcCtD
Paroxetine—Thrombocytopenia—Carmustine—malignant glioma	0.000258	0.00178	CcSEcCtD
Paroxetine—Tachycardia—Carmustine—malignant glioma	0.000257	0.00177	CcSEcCtD
Paroxetine—Confusional state—Temozolomide—malignant glioma	0.000256	0.00177	CcSEcCtD
Paroxetine—HTR2A—cerebellum—malignant glioma	0.000256	0.00423	CbGeAlD
Paroxetine—CYP2B6—brain—malignant glioma	0.000255	0.00421	CbGeAlD
Paroxetine—Oedema—Temozolomide—malignant glioma	0.000254	0.00175	CcSEcCtD
Paroxetine—Anaphylactic shock—Temozolomide—malignant glioma	0.000254	0.00175	CcSEcCtD
Paroxetine—Infection—Temozolomide—malignant glioma	0.000253	0.00174	CcSEcCtD
Paroxetine—Nervous system disorder—Temozolomide—malignant glioma	0.000249	0.00172	CcSEcCtD
Paroxetine—Thrombocytopenia—Temozolomide—malignant glioma	0.000249	0.00172	CcSEcCtD
Paroxetine—Skin disorder—Temozolomide—malignant glioma	0.000247	0.0017	CcSEcCtD
Paroxetine—Hypotension—Carmustine—malignant glioma	0.000246	0.00169	CcSEcCtD
Paroxetine—Hyperhidrosis—Temozolomide—malignant glioma	0.000246	0.00169	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Carmustine—malignant glioma	0.00024	0.00165	CcSEcCtD
Paroxetine—CYP2D6—central nervous system—malignant glioma	0.000239	0.00394	CbGeAlD
Paroxetine—Insomnia—Carmustine—malignant glioma	0.000238	0.00164	CcSEcCtD
Paroxetine—ABCB1—medulla oblongata—malignant glioma	0.000237	0.00392	CbGeAlD
Paroxetine—Paraesthesia—Carmustine—malignant glioma	0.000236	0.00163	CcSEcCtD
Paroxetine—Dyspnoea—Carmustine—malignant glioma	0.000234	0.00162	CcSEcCtD
Paroxetine—Somnolence—Carmustine—malignant glioma	0.000234	0.00161	CcSEcCtD
Paroxetine—CYP2D6—cerebellum—malignant glioma	0.000233	0.00385	CbGeAlD
Paroxetine—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.000232	0.0016	CcSEcCtD
Paroxetine—Insomnia—Temozolomide—malignant glioma	0.00023	0.00159	CcSEcCtD
Paroxetine—Decreased appetite—Carmustine—malignant glioma	0.000229	0.00158	CcSEcCtD
Paroxetine—Paraesthesia—Temozolomide—malignant glioma	0.000228	0.00157	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Carmustine—malignant glioma	0.000227	0.00157	CcSEcCtD
Paroxetine—Dyspnoea—Temozolomide—malignant glioma	0.000227	0.00156	CcSEcCtD
Paroxetine—Somnolence—Temozolomide—malignant glioma	0.000226	0.00156	CcSEcCtD
Paroxetine—Constipation—Carmustine—malignant glioma	0.000225	0.00155	CcSEcCtD
Paroxetine—Pain—Carmustine—malignant glioma	0.000225	0.00155	CcSEcCtD
Paroxetine—Dyspepsia—Temozolomide—malignant glioma	0.000224	0.00154	CcSEcCtD
Paroxetine—Decreased appetite—Temozolomide—malignant glioma	0.000221	0.00152	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Temozolomide—malignant glioma	0.000219	0.00151	CcSEcCtD
Paroxetine—Fatigue—Temozolomide—malignant glioma	0.000219	0.00151	CcSEcCtD
Paroxetine—Pain—Temozolomide—malignant glioma	0.000217	0.0015	CcSEcCtD
Paroxetine—Constipation—Temozolomide—malignant glioma	0.000217	0.0015	CcSEcCtD
Paroxetine—ABCB1—midbrain—malignant glioma	0.000217	0.00358	CbGeAlD
Paroxetine—Feeling abnormal—Carmustine—malignant glioma	0.000217	0.00149	CcSEcCtD
Paroxetine—Gastrointestinal pain—Carmustine—malignant glioma	0.000215	0.00148	CcSEcCtD
Paroxetine—ABCB1—spinal cord—malignant glioma	0.000212	0.00349	CbGeAlD
Paroxetine—Feeling abnormal—Temozolomide—malignant glioma	0.000209	0.00144	CcSEcCtD
Paroxetine—HTR2A—brain—malignant glioma	0.000208	0.00343	CbGeAlD
Paroxetine—Body temperature increased—Carmustine—malignant glioma	0.000208	0.00143	CcSEcCtD
Paroxetine—Abdominal pain—Carmustine—malignant glioma	0.000208	0.00143	CcSEcCtD
Paroxetine—Gastrointestinal pain—Temozolomide—malignant glioma	0.000208	0.00143	CcSEcCtD
Paroxetine—Urticaria—Temozolomide—malignant glioma	0.000202	0.00139	CcSEcCtD
Paroxetine—Abdominal pain—Temozolomide—malignant glioma	0.000201	0.00139	CcSEcCtD
Paroxetine—Body temperature increased—Temozolomide—malignant glioma	0.000201	0.00139	CcSEcCtD
Paroxetine—Hypersensitivity—Carmustine—malignant glioma	0.000194	0.00134	CcSEcCtD
Paroxetine—CYP2D6—brain—malignant glioma	0.00019	0.00313	CbGeAlD
Paroxetine—Asthenia—Carmustine—malignant glioma	0.000189	0.0013	CcSEcCtD
Paroxetine—Hypersensitivity—Temozolomide—malignant glioma	0.000187	0.00129	CcSEcCtD
Paroxetine—Asthenia—Temozolomide—malignant glioma	0.000182	0.00126	CcSEcCtD
Paroxetine—Diarrhoea—Carmustine—malignant glioma	0.00018	0.00124	CcSEcCtD
Paroxetine—Pruritus—Temozolomide—malignant glioma	0.00018	0.00124	CcSEcCtD
Paroxetine—Dizziness—Carmustine—malignant glioma	0.000174	0.0012	CcSEcCtD
Paroxetine—Diarrhoea—Temozolomide—malignant glioma	0.000174	0.0012	CcSEcCtD
Paroxetine—ABCB1—central nervous system—malignant glioma	0.000172	0.00283	CbGeAlD
Paroxetine—Dizziness—Temozolomide—malignant glioma	0.000168	0.00116	CcSEcCtD
Paroxetine—ABCB1—cerebellum—malignant glioma	0.000168	0.00277	CbGeAlD
Paroxetine—Vomiting—Carmustine—malignant glioma	0.000167	0.00115	CcSEcCtD
Paroxetine—Rash—Carmustine—malignant glioma	0.000166	0.00114	CcSEcCtD
Paroxetine—Dermatitis—Carmustine—malignant glioma	0.000166	0.00114	CcSEcCtD
Paroxetine—Headache—Carmustine—malignant glioma	0.000165	0.00114	CcSEcCtD
Paroxetine—Vomiting—Temozolomide—malignant glioma	0.000162	0.00111	CcSEcCtD
Paroxetine—Rash—Temozolomide—malignant glioma	0.00016	0.0011	CcSEcCtD
Paroxetine—Dermatitis—Temozolomide—malignant glioma	0.00016	0.0011	CcSEcCtD
Paroxetine—Headache—Temozolomide—malignant glioma	0.000159	0.0011	CcSEcCtD
Paroxetine—Nausea—Carmustine—malignant glioma	0.000156	0.00108	CcSEcCtD
Paroxetine—Nausea—Temozolomide—malignant glioma	0.000151	0.00104	CcSEcCtD
Paroxetine—ABCB1—brain—malignant glioma	0.000136	0.00225	CbGeAlD
Paroxetine—CHRM5—Signaling by GPCR—PIK3CA—malignant glioma	7.16e-06	7.74e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—HIF1A—malignant glioma	7.14e-06	7.72e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MDM2—malignant glioma	7.13e-06	7.71e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—RAF1—malignant glioma	7.11e-06	7.68e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—GSTP1—malignant glioma	7.07e-06	7.64e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CAV1—malignant glioma	7.04e-06	7.6e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—ERBB2—malignant glioma	7.03e-06	7.6e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CAV1—malignant glioma	7e-06	7.56e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CAV1—malignant glioma	6.98e-06	7.54e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CXCL8—malignant glioma	6.96e-06	7.52e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—KDR—malignant glioma	6.96e-06	7.52e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—PIK3CB—malignant glioma	6.94e-06	7.5e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—KDR—malignant glioma	6.92e-06	7.48e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CAV1—malignant glioma	6.91e-06	7.47e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—KDR—malignant glioma	6.9e-06	7.45e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CAT—malignant glioma	6.88e-06	7.43e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—KDR—malignant glioma	6.83e-06	7.38e-05	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—AKT1—malignant glioma	6.73e-06	7.27e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	6.7e-06	7.24e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—F2—malignant glioma	6.7e-06	7.24e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—FN1—malignant glioma	6.7e-06	7.24e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PIK3CD—malignant glioma	6.68e-06	7.22e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CXCL8—malignant glioma	6.67e-06	7.2e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CASP3—malignant glioma	6.66e-06	7.2e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—F2—malignant glioma	6.66e-06	7.2e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—FN1—malignant glioma	6.66e-06	7.2e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—GSTP1—malignant glioma	6.66e-06	7.2e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—IL2—malignant glioma	6.65e-06	7.19e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—F2—malignant glioma	6.64e-06	7.18e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—FN1—malignant glioma	6.64e-06	7.18e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—BAD—malignant glioma	6.62e-06	7.15e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—GSTP1—malignant glioma	6.6e-06	7.13e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—BAD—malignant glioma	6.58e-06	7.11e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—F2—malignant glioma	6.58e-06	7.11e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—FN1—malignant glioma	6.58e-06	7.11e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—BAD—malignant glioma	6.56e-06	7.09e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—NOTCH1—malignant glioma	6.55e-06	7.08e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PIK3CG—malignant glioma	6.54e-06	7.06e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—NOTCH1—malignant glioma	6.52e-06	7.04e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—NOTCH1—malignant glioma	6.5e-06	7.02e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—BAD—malignant glioma	6.5e-06	7.02e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—NCOR1—malignant glioma	6.49e-06	7.02e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CAT—malignant glioma	6.48e-06	7e-05	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—AKT1—malignant glioma	6.44e-06	6.96e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—NOTCH1—malignant glioma	6.44e-06	6.95e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CAT—malignant glioma	6.42e-06	6.94e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CD80—malignant glioma	6.42e-06	6.94e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PIK3CG—malignant glioma	6.41e-06	6.93e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—APC—malignant glioma	6.41e-06	6.93e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CD80—malignant glioma	6.39e-06	6.9e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CASP3—malignant glioma	6.38e-06	6.9e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PIK3CG—malignant glioma	6.38e-06	6.89e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—APC—malignant glioma	6.38e-06	6.89e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—IL2—malignant glioma	6.37e-06	6.88e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CD80—malignant glioma	6.37e-06	6.88e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—APC—malignant glioma	6.35e-06	6.87e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PIK3CG—malignant glioma	6.35e-06	6.87e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—EGF—malignant glioma	6.34e-06	6.85e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PPARG—malignant glioma	6.31e-06	6.82e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CD80—malignant glioma	6.3e-06	6.81e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—EGF—malignant glioma	6.3e-06	6.81e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MMP9—malignant glioma	6.3e-06	6.8e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PTPN11—malignant glioma	6.3e-06	6.8e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—APC—malignant glioma	6.29e-06	6.8e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PIK3CG—malignant glioma	6.29e-06	6.8e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—EGF—malignant glioma	6.28e-06	6.79e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PTPN11—malignant glioma	6.26e-06	6.77e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—PTEN—malignant glioma	6.26e-06	6.76e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PTPN11—malignant glioma	6.24e-06	6.75e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—EGF—malignant glioma	6.22e-06	6.72e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PTPN11—malignant glioma	6.18e-06	6.68e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—NCOR1—malignant glioma	6.12e-06	6.61e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—AKT1—malignant glioma	6.11e-06	6.6e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—CAV1—malignant glioma	6.08e-06	6.57e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—NCOR1—malignant glioma	6.07e-06	6.56e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MMP9—malignant glioma	6.03e-06	6.52e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—BRAF—malignant glioma	6.02e-06	6.51e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—PTEN—malignant glioma	6e-06	6.48e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—BRAF—malignant glioma	5.99e-06	6.48e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—BRAF—malignant glioma	5.97e-06	6.45e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—BRAF—malignant glioma	5.92e-06	6.39e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—AKT2—malignant glioma	5.86e-06	6.34e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—AKT1—malignant glioma	5.85e-06	6.32e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—EGFR—malignant glioma	5.84e-06	6.31e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—AKT2—malignant glioma	5.83e-06	6.3e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PIK3CB—malignant glioma	5.82e-06	6.29e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—AKT2—malignant glioma	5.81e-06	6.28e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—EGFR—malignant glioma	5.81e-06	6.28e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	5.81e-06	6.27e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—EGFR—malignant glioma	5.79e-06	6.26e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PTGS2—malignant glioma	5.77e-06	6.24e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—AKT2—malignant glioma	5.76e-06	6.22e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PIK3CD—malignant glioma	5.75e-06	6.21e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—EGFR—malignant glioma	5.73e-06	6.2e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—VEGFA—malignant glioma	5.65e-06	6.11e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PIK3CD—malignant glioma	5.63e-06	6.09e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PIK3CD—malignant glioma	5.6e-06	6.06e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—STAT3—malignant glioma	5.6e-06	6.05e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PIK3CD—malignant glioma	5.59e-06	6.04e-05	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—PIK3CA—malignant glioma	5.58e-06	6.03e-05	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—PIK3CA—malignant glioma	5.55e-06	6e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PIK3CG—malignant glioma	5.54e-06	5.98e-05	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—PIK3CA—malignant glioma	5.53e-06	5.98e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PIK3CD—malignant glioma	5.53e-06	5.98e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—KRAS—malignant glioma	5.52e-06	5.96e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—KRAS—malignant glioma	5.49e-06	5.93e-05	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—PIK3CA—malignant glioma	5.48e-06	5.92e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—KRAS—malignant glioma	5.47e-06	5.91e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—KRAS—malignant glioma	5.42e-06	5.85e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—VEGFA—malignant glioma	5.41e-06	5.85e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—FGF2—malignant glioma	5.39e-06	5.83e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—FGF2—malignant glioma	5.37e-06	5.8e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—STAT3—malignant glioma	5.36e-06	5.79e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—FGF2—malignant glioma	5.35e-06	5.78e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PPARG—malignant glioma	5.34e-06	5.77e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—FGF2—malignant glioma	5.3e-06	5.72e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CAV1—malignant glioma	5.29e-06	5.72e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MYC—malignant glioma	5.2e-06	5.62e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—EGFR—malignant glioma	5.09e-06	5.5e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—PIK3CA—malignant glioma	5.07e-06	5.48e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MDM2—malignant glioma	5.05e-06	5.45e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—PIK3CA—malignant glioma	5.04e-06	5.45e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PTEN—malignant glioma	5.03e-06	5.44e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—RAF1—malignant glioma	5.03e-06	5.44e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—PIK3CA—malignant glioma	5.02e-06	5.43e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MDM2—malignant glioma	5.02e-06	5.43e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PIK3CB—malignant glioma	5.01e-06	5.41e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MDM2—malignant glioma	5e-06	5.41e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—RAF1—malignant glioma	5e-06	5.41e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CAV1—malignant glioma	4.99e-06	5.39e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—RAF1—malignant glioma	4.99e-06	5.39e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MYC—malignant glioma	4.98e-06	5.38e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—ERBB2—malignant glioma	4.98e-06	5.38e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—PIK3CA—malignant glioma	4.98e-06	5.38e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PTGS2—malignant glioma	4.96e-06	5.36e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MDM2—malignant glioma	4.96e-06	5.36e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—ERBB2—malignant glioma	4.95e-06	5.35e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CAV1—malignant glioma	4.95e-06	5.34e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—RAF1—malignant glioma	4.94e-06	5.34e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—ERBB2—malignant glioma	4.93e-06	5.33e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PIK3CB—malignant glioma	4.91e-06	5.31e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—ERBB2—malignant glioma	4.89e-06	5.28e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PIK3CB—malignant glioma	4.88e-06	5.28e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—EGFR—malignant glioma	4.87e-06	5.27e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PIK3CB—malignant glioma	4.87e-06	5.26e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PIK3CD—malignant glioma	4.87e-06	5.26e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PIK3CG—malignant glioma	4.82e-06	5.21e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PIK3CB—malignant glioma	4.82e-06	5.21e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—KRAS—malignant glioma	4.81e-06	5.19e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	4.73e-06	5.11e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CXCL8—malignant glioma	4.72e-06	5.1e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CXCL8—malignant glioma	4.69e-06	5.07e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CXCL8—malignant glioma	4.68e-06	5.06e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PPARG—malignant glioma	4.65e-06	5.03e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CXCL8—malignant glioma	4.63e-06	5.01e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—KRAS—malignant glioma	4.6e-06	4.97e-05	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—AKT1—malignant glioma	4.56e-06	4.93e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PIK3CG—malignant glioma	4.54e-06	4.91e-05	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—AKT1—malignant glioma	4.53e-06	4.9e-05	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—AKT1—malignant glioma	4.52e-06	4.88e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CASP3—malignant glioma	4.52e-06	4.88e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IL2—malignant glioma	4.51e-06	4.87e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PIK3CG—malignant glioma	4.5e-06	4.87e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CASP3—malignant glioma	4.49e-06	4.86e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IL2—malignant glioma	4.49e-06	4.85e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CASP3—malignant glioma	4.48e-06	4.84e-05	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—AKT1—malignant glioma	4.48e-06	4.84e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IL2—malignant glioma	4.47e-06	4.83e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CASP3—malignant glioma	4.44e-06	4.79e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IL2—malignant glioma	4.43e-06	4.79e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—PIK3CA—malignant glioma	4.42e-06	4.77e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PPARG—malignant glioma	4.39e-06	4.74e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PPARG—malignant glioma	4.35e-06	4.7e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PTEN—malignant glioma	4.33e-06	4.68e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TP53—malignant glioma	4.27e-06	4.62e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MMP9—malignant glioma	4.27e-06	4.61e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MMP9—malignant glioma	4.25e-06	4.59e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PTEN—malignant glioma	4.24e-06	4.59e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PIK3CB—malignant glioma	4.24e-06	4.58e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PIK3CD—malignant glioma	4.24e-06	4.58e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MMP9—malignant glioma	4.23e-06	4.57e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—PIK3CA—malignant glioma	4.23e-06	4.57e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PTEN—malignant glioma	4.22e-06	4.56e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PTEN—malignant glioma	4.21e-06	4.55e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PTGS2—malignant glioma	4.2e-06	4.54e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MMP9—malignant glioma	4.19e-06	4.53e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PTEN—malignant glioma	4.17e-06	4.5e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—AKT1—malignant glioma	4.14e-06	4.47e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—AKT1—malignant glioma	4.12e-06	4.45e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—AKT1—malignant glioma	4.1e-06	4.44e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TP53—malignant glioma	4.09e-06	4.42e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—AKT1—malignant glioma	4.07e-06	4.39e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PIK3CD—malignant glioma	3.99e-06	4.32e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PIK3CD—malignant glioma	3.96e-06	4.28e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—VEGFA—malignant glioma	3.83e-06	4.14e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—VEGFA—malignant glioma	3.81e-06	4.12e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—VEGFA—malignant glioma	3.8e-06	4.11e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—STAT3—malignant glioma	3.8e-06	4.1e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—STAT3—malignant glioma	3.78e-06	4.08e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—VEGFA—malignant glioma	3.76e-06	4.07e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—STAT3—malignant glioma	3.76e-06	4.07e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—STAT3—malignant glioma	3.73e-06	4.03e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PIK3CB—malignant glioma	3.7e-06	3.99e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PTEN—malignant glioma	3.67e-06	3.96e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PTGS2—malignant glioma	3.66e-06	3.96e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—AKT1—malignant glioma	3.61e-06	3.9e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PIK3CA—malignant glioma	3.55e-06	3.84e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MYC—malignant glioma	3.53e-06	3.81e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MYC—malignant glioma	3.51e-06	3.79e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MYC—malignant glioma	3.5e-06	3.78e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PIK3CB—malignant glioma	3.48e-06	3.76e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MYC—malignant glioma	3.46e-06	3.74e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—AKT1—malignant glioma	3.46e-06	3.73e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PIK3CB—malignant glioma	3.45e-06	3.73e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PTGS2—malignant glioma	3.45e-06	3.73e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—EGFR—malignant glioma	3.45e-06	3.73e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—EGFR—malignant glioma	3.43e-06	3.71e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PTGS2—malignant glioma	3.42e-06	3.7e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—EGFR—malignant glioma	3.42e-06	3.7e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—EGFR—malignant glioma	3.39e-06	3.66e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—KRAS—malignant glioma	3.26e-06	3.52e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—KRAS—malignant glioma	3.24e-06	3.5e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—KRAS—malignant glioma	3.23e-06	3.49e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—KRAS—malignant glioma	3.2e-06	3.46e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PTEN—malignant glioma	3.19e-06	3.45e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PIK3CA—malignant glioma	3.05e-06	3.3e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PTEN—malignant glioma	3.01e-06	3.25e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PIK3CA—malignant glioma	2.99e-06	3.24e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PTEN—malignant glioma	2.98e-06	3.22e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PIK3CA—malignant glioma	2.98e-06	3.22e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PIK3CA—malignant glioma	2.97e-06	3.21e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PIK3CA—malignant glioma	2.94e-06	3.18e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—AKT1—malignant glioma	2.9e-06	3.13e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TP53—malignant glioma	2.9e-06	3.13e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TP53—malignant glioma	2.88e-06	3.11e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TP53—malignant glioma	2.87e-06	3.1e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TP53—malignant glioma	2.84e-06	3.07e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PIK3CA—malignant glioma	2.59e-06	2.79e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—AKT1—malignant glioma	2.49e-06	2.7e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—AKT1—malignant glioma	2.45e-06	2.64e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—AKT1—malignant glioma	2.43e-06	2.63e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—AKT1—malignant glioma	2.42e-06	2.62e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—AKT1—malignant glioma	2.4e-06	2.59e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PIK3CA—malignant glioma	2.25e-06	2.43e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PIK3CA—malignant glioma	2.12e-06	2.29e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—AKT1—malignant glioma	2.11e-06	2.28e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PIK3CA—malignant glioma	2.1e-06	2.27e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—AKT1—malignant glioma	1.84e-06	1.99e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—AKT1—malignant glioma	1.73e-06	1.87e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—AKT1—malignant glioma	1.72e-06	1.86e-05	CbGpPWpGaD
